United Kingdom (UK)
Recombinant monoclonal antibody to Rotavirus. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 2B10 (ARP1; VHH1).
Alternative Name(s) of Target: RRV; Outer capsid glycoprotein;
Immunogen: The original antibody was generated by immunizing a llama subcutaneously and intramuscularly with 5×10^12 pfu of Rhesus rotavirus strain RRV (serotype G3).
Specificity: This antibody binds antigens expressed on rotavirus particles. Rotaviruses are the most common cause of infantile diarrhea in the world and most children get infected during the first 5 years of life.
Application Notes: This antibody is capable of binding rotavirus particles present in serum samples in an ELISA. This antibody was capable of reducing the morbidity of rotavirus induced diarrhea in vivo in mice (PMID: 16616802). This antibody is capable of neutralizing rotavirus in vitro and in vivo (PMID: 17083044). This antibody is capable of neutralizing CK5 strain of rotavirus in an in vitro plaque assay with an IC50 of approximately 3 nM. Daily oral administration of 50 or 100µg 2B10 nanobody could either prevent diarrhea or reduce the number of days with diarrhea per mouse pup model (PMID: 21939690). The mouse IgG1 Fc-fusion version of this antibody confers significantly increased protection against rotavirus in a neonatal mouse model of rotavirus-induced diarrhea by reducing the prevalence, duration and severity of diarrhea and the viral load in the small intestines (PMID: 27439689).
Antibody first published in:
Van der Vaart et al. Reduction in morbidity of rotavirus induced diarrhea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine. 2006 May 8;24(19):4130-7. PMID:16616802
Note on publication:
Describes the generation of llama heavy chain antibodies against rotavirus that are capable of reducing morbidity of rotavirus induced diarrhea